...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids
【24h】

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

机译：糖皮质激素治疗患者每年一次唑来膦酸与每日口服利塞膦酸盐静脉输注对骨转换指标的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO). Methods: Patients were randomly stratified according to the duration of pre-study glucocorticoid therapy [prevention subpopulation (ZOL, n = 144; RIS, n = 144) ≤3 months, treatment subpopulation (ZOL, n = 272; RIS, n = 273) >3 months]. Changes in β-C-terminal telopeptides of type 1 collagen (b-CTx), N-terminal telopeptide of type I collagen (NTx), procollagen type 1 N-terminal propeptide (P1NP) and bone-specific alkaline phosphatase (BSAP) from baseline were measured on day 10 and months 3, 6 and 12. Results: At most time points, there were significantly greater reductions (P<0.05) in the concentrations of serum β-CTx, P1NP and BSAP and urine NTx in subjects on ZOL compared with RIS in both males and females of the treatment and prevention subpopulations. In pre- and post-menopausal women, there were significantly greater reductions in the concentrations of BTMs with ZOL compared with RIS. At 12 months, ZOL had significantly greater reductions compared with RIS (P<0.05) for β-CTx, P1NP, BSAP and NTx levels, independent of glucocorticoid dose. Conclusions: Once-yearly i.v. infusion of ZOL 5mg was well tolerated in different subgroups of GIO patients. ZOL was non-inferior to RIS and even superior to RIS in the response of BTMs in GIO patients.
机译：目的：长期使用糖皮质激素伴有快速骨质流失;但是，双膦酸盐的早期治疗可防止骨质流失并降低骨折风险。这项研究的目的是研究两种双膦酸盐（静脉注射）的作用。糖皮质激素诱导的骨质疏松症（GIO）患者的骨转换指标（BTM）上唑来膦酸（ZOL）与口服瑞斯膦酸盐（RIS）的关系。方法：根据研究前糖皮质激素治疗的持续时间对患者进行分层[预防亚群（ZOL，n = 144; RIS，n = 144）≤3个月，治疗亚群（ZOL，n = 272; RIS，n = 273） ）> 3个月]。 1型胶原的β-C端端肽（b-CTx），I型胶原的N端端肽（NTx），前胶原1型N端前肽（P1NP）和骨特异性碱性磷酸酶（BSAP）的变化在第10天以及第3、6和12个月测量基线。结果：在大多数时间点，接受ZOL治疗的受试者的血清β-CTx，P1NP和BSAP和尿液NTx浓度显着降低（P <0.05）在男性和女性的治疗和预防亚人群中与RIS进行比较。在绝经前和绝经后的妇女中，与RIS相比，使用ZOL的BTM浓度降低幅度更大。与糖皮质激素剂量无关，β-CTx，P1NP，BSAP和NTx水平在12个月时，与RIS相比，ZOL的降低显着更大（P <0.05）。结论：每年一次i.v.在GIO患者的不同亚组中，对ZOL 5mg的输注耐受良好。 ZOL在GIO患者的BTM反应方面不劣于RIS，甚至优于RIS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号